Belite Bio, Inc
BLTE
$183.16
-$9.69-5.03%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 286.11% | 272.23% | 172.04% | 102.17% | 47.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.54% | 90.42% | 47.92% | 42.49% | 26.30% |
| Operating Income | -110.54% | -90.42% | -47.92% | -42.49% | -26.30% |
| Income Before Tax | -114.76% | -88.89% | -39.94% | -30.53% | -14.28% |
| Income Tax Expenses | -- | -100.00% | -100.00% | -100.00% | -33.33% |
| Earnings from Continuing Operations | -114.73% | -88.86% | -39.91% | -30.49% | -14.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.73% | -88.86% | -39.91% | -30.49% | -14.26% |
| EBIT | -110.54% | -90.42% | -47.92% | -42.49% | -26.30% |
| EBITDA | -110.92% | -90.70% | -47.94% | -42.43% | -26.13% |
| EPS Basic | -94.39% | -73.26% | -26.45% | -15.75% | 4.71% |
| Normalized Basic EPS | -123.84% | -83.84% | -144.65% | -144.65% | -144.65% |
| EPS Diluted | -94.39% | -73.26% | -26.45% | -15.75% | 4.71% |
| Normalized Diluted EPS | -123.84% | -83.84% | -144.65% | -144.65% | -144.65% |
| Average Basic Shares Outstanding | 9.79% | 8.69% | 9.67% | 12.12% | 19.32% |
| Average Diluted Shares Outstanding | 9.79% | 8.69% | 9.67% | 12.12% | 19.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |